Cyclacel Pharmaceuticals IncNASDAQ:CYCCNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.7800
- TODAY'S CHANGE (%)-0.0700 (-3.7838%)
- Bid / Lots1.5200/ 2
- Ask / Lots1.8600/ 2
- Open / Previous Close1.8900 / 1.8500
- Day Range
- 52 Week Range
- Volume10,391
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYCC |
|---|---|---|
| 09:32 ET | 100 | 1.89 |
| 10:21 ET | 250 | 1.8983 |
| 10:33 ET | 4100 | 1.95 |
| 10:48 ET | 3609 | 1.9399 |
| 10:51 ET | 110 | 1.7717 |
| 10:53 ET | 100 | 1.84 |
| 11:44 ET | 140 | 1.8799 |
| 12:54 ET | 170 | 1.81 |
| 01:35 ET | 500 | 1.8015 |
| 02:33 ET | 100 | 1.78 |
Apr 1, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cyclacel Pharmaceuticals Inc | 2.3M | -0.1x | --- |
Regen BioPharma Inc | 2.6M | -1.9x | --- |
Fresh2 Group Ltd | 12.0M | -0.1x | --- |
Hi-Great Group Holding Co | 1.8M | 148.3x | --- |
Herborium Group Inc | 1.1M | 0.0x | --- |
CNBX Pharmaceuticals Inc | 354.7K | -0.2x | --- |
Company Information
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Contact Information
- Headquarters
- 200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811
- Phone
- 908-517-7330
- Fax
- 866-271-3466
Executives
- Independent Chairman of the Board
- Christopher Henney
- President, Chief Executive Officer, Director
- Spiro Rombotis
- Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
- Paul Mcbarron
- Interim Chief Medical Officer, Director
- Brian Schwartz
- Independent Director
- Samuel Barker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3M |
|---|---|
Revenue (TTM) | $420.0K |
Shares Outstanding | 1.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-26.72 |
Book Value | $0.57 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,060.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
